Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2022-09-05 AGM Information
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Annual General Meeting
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) for Beta Drugs Limited, dated 5th September 2022, detailing the agenda items to be discussed at the AGM scheduled for 29th September 2022. It includes items such as adoption of financial statements, appointment and re-appointment of directors, ratification of auditor remuneration, and revisions of remuneration for directors. The document is a formal notice sent to shareholders to inform them about the AGM and the business to be transacted. It does not contain the actual financial statements or detailed reports but rather the agenda and resolutions to be considered at the meeting. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices of the meeting and agenda items.
2022-09-05 English
Book Closure
AGM Information Classification · 90% confidence The document text is very short (285 characters) and appears to be a notice related to book closure dates for an Annual General Meeting (AGM). It mentions 'LTth Annual General Meeting of the Company' and specific dates for book closure, which is typical for announcements related to shareholder meetings. There is no detailed financial data, no full report, and no indication of a report being attached or published. This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related notices.
2022-08-30 English
Annual General Meeting
AGM Information Classification · 95% confidence The document is a short letter informing the stock exchange about the upcoming 17th Annual General Meeting (AGM) of Beta Drugs Limited, including the date, time, and venue. It mentions that the Notice of the AGM and the Annual Report for the financial year 2021-22 will be submitted later once dispatched to shareholders. The document does not contain the actual AGM materials or the Annual Report itself, but is an announcement of the meeting and related report availability. The document length is only 1101 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE, this is a Report Publication Announcement related to the AGM and Annual Report, but not the reports themselves. The best fitting category is AGM Information (AGM-R) since it concerns the AGM notice and related information.
2022-08-30 English
Outcome of Board Meeting
Regulatory Filings Classification · 90% confidence The document text is extremely short (248 characters) and appears to be a fragment or incomplete snippet with no clear financial data, report title, or regulatory references. It does not contain any substantive financial information, management discussion, or announcement content. Given the lack of content and context, and the fact that it does not fit any specific report or announcement category, the best classification is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not neatly fit elsewhere.
2022-08-30 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a board meeting held on 20th July 2022 by Beta Drugs Limited. It includes approvals of appointments of auditors (cost auditor, secretarial auditor, internal auditor) for the financial year 2022-23, and recommendations for re-appointment of independent directors subject to shareholder approval. The document contains detailed profiles of the appointed auditors and directors, which is typical for disclosures related to board and management changes. There is no financial data or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a voting result declaration (DVA) since it only recommends re-appointments subject to shareholder approval. The document is not a proxy solicitation or remuneration report. The focus is on board meeting outcomes and management appointments. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2022-07-20 English
General updates
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by Link Intime India Pvt. Ltd. under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It confirms the processing of dematerialisation requests for the quarter ended June 30, 2022, including acceptance/rejection of securities and compliance with SEBI circulars. The document is a regulatory compliance certificate related to securities dematerialisation and does not contain financial statements, management discussion, or detailed report content. It is not an annual or interim report, earnings release, or any other detailed financial or governance report. The document is short (2258 characters) and serves as a compliance confirmation rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory compliance documents that do not fit other specific categories.
2022-07-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.